Meeting
2022 ASCO Annual Meeting
EA2183: A phase III study of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma.
Authors
Nataliya Volodymyrivna Uboha
UW Carbone Cancer Center, Madison, WI
Nataliya Volodymyrivna Uboha , Noah Graham , Lakshmi Rajdev , Michael K. Gibson , George A. Fisher Jr., Steven H. Lin , Bapsi Chakravarthy , Peter J. O'Dwyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT04248452
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4162)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4162
Abstract #
TPS4162
Poster Bd #
146b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
First Author: Samuel J Klempner
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
First Author: Manish A. Shah
Poster
2017 Gastrointestinal Cancers Symposium
Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
First Author: Yelena Yuriy Janjigian
Poster
2023 ASCO Annual Meeting
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
First Author: Haeseong Park